$GILD trend reversal ? it maybe a trend reversal for $GILD
the stock has good fundamentals ,, and the company was providing COVID-19 medicine for free ,, now they put a price for each patient treatment course nearly 2000$
so it maybe will push the company earnings .
it is not a buy or sell recommendation ,, im here to share my ideas .
GILD
GILD: need to break the $67 barrierwe're still holding GILD and now it's making another attempt at recovering from the recent drop
we need to break the $67 and stay above it for couple of sessions - with strong volume - to flag a proper recovery - the prior attempt for a breakout failed - this time there's some momentum and demand - but still light.
we'll see
Long and hold $GSK ($MRNA $GILD $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com
GSK
Entry $39.70
Target 1 $42.45
Target 2 $45.50
Target 3 $48
stoploss 38.70
Why this play?
There are 4 general approaches to the Covid vaccine.
1.A "killed" coronavirus that will get recognized as foreign matter in the blood. (Sinovac/Dynavax)
2.Coronavirus proteins themselves, produced industrially in outside cell cultures,
which will be recognized as foreign matter in the blood. (GlaxoSmithKline/Sanofi, Novavax)
3.A different virus (human or ape adenovirus, measles, etc) that is engineered
to include genetic components coding for the SARS-CoV-2 spike proteins,
which causes the body to then produce them. (CanSino, Oxford, J&J,
Merck/Themis)
4.DNA or RNA that will be taken up by cells and will cause them to make
coronavirus proteins. (Moderna, Innovio,
BioNTech/Pfizer)
GSK is #2, there is only 1 other big company doing this approach and that is NVAX.
We are betting on the fact that if they are successful, they could have super run like NVAX.
What is GSk?
www.gsk.com
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
LONG $AZN Covid wave 2 play ($MRNA $GILD $INO $SPY)see full chart at www.tradingview.com
AZN
Entry $54 area
Target $57
stoploss 53
Why this play?
Covid Vaccine stocks are hot right now, cases are rising = easy money.
What is AZN?
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology,
cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.
The company serves primary care and specialty care physicians through distributors and local representative offices.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
Gilead is heading to the all time high Gilead Sciences is one of the largest antiviral producers in the world. Covid 19 pandemic showed that the greatest threat to the existence of humanity comes from Viral infections not wars or other natural disasters.
Gilead has hundreds of untested patented antiviral agents that can helps in these kind of situations. Finding the cure for the hardest diseases like HIV, HCV and now Covid 19, is a good proof how strategic this company is.
Gilead fundamentally is strong too. More than 20B cash in the accounts speeds up the growth. They have bought 3 small cancer research companies in 3 months. In my opinion, Gilead has started a bulish longterm trend and with the help of Remdesivir sales it can reach the all time high.
I m long GILD and I will add to the position if it breaks the resistance at 78.
$AZN Covid wave 2 play ($MRNA $GILD $INO $SPY)see full chart at www.tradingview.com
AZN
Entry $51.68
Target $53
stoploss $50
Why this play?
they are really trying to push the Covid wave 2 case, and the market is crash. so if wave 2 really comes, these stocks should pump even further.
What is AZN?
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology,
cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.
The company serves primary care and specialty care physicians through distributors and local representative offices.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
ridethepig | Gilead to ATH's with Remdesivir📍 The effect of Remdesivir...
The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in.
Compare the following two diagrams:
Phase III trials & Chinese red carpet
Buyers maintaining a strong floor.
In the first, you will notice how once we got the break of the channel buyers were allowed to go wandering all the way to the target on grounds of safety! The second wave looks inevitable despite the political fairydust around re-openings, stimulus is running out and now the attempt to reinstate pockets of further lockdowns will make activity immovable.
Thus the question, why adding more Gilead?
When building a long/short portfolio, we must add hedges and blocks accordingly. The strategic protection with Gilead is pragmatic, 450 million new customers unlocked via European clearance & we already got the ✅ for the red carpet from China. Complacency around the virus is remarkable, UK cheerleading "Super Saturday" and US "Independence Day" ... who would have thought we are in the middle of a pandemic. In any case... An attractive constellation for a swing towards all time highs.
Thanks as usual for keeping the feedback coming 👍 or 👎
COVID-19 Vaccine, 1st Effective Drug, USA Secures 500,000 DosesHHS secures 500,000 doses of remdesivir.
The Trump administration has secured 500,000 doses of remdesivir, the first drug shown to be effective at treating hospitalized coronavirus patients, ensuring these doses will be for U.S. use.
This could mean huge profits for GILD.
Indicators are starting to turn up, Bullish.
Daily Chart is turning Bullish.
I think if the stock breaks above the $77.00 range, it's going to spike.
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
I'm loving GILD here. Signals on the daily/hrly chartsNASDAQ:GILD
My custom indicators have signaled multiple times on the daily and hourly charts. Our target price is 80.80+
My calls are already in the green and I'm ready. I should have shorted it after it signaled "short" in the meantime.
Bars below turned from red to green which is a positive trend indicator
Long on GILD - good fundamentals - nice chartGILD broke out of a multiyear downtrend in February. Volume after breakout increased a lot. Now we experienced some type of consolidation/correction after the breakout. I think this is a good moment to buy GILD and hold it for a longer period. Key figures like P/E, P/B and P/S look good.
First target around 85$.